The Hidden System Deciding Where You Get Your Medicine

The Hidden System Deciding Where You Get Your Medicine

Timothy Lesaca MD

Mar 05, 2026

Pennsylvania’s pharmacy crisis has become a familiar story of modern American healthcare: a local institution weakens, patients feel the loss immediately, and the real power lies somewhere far from the neighborhood where the damage is done. Now some Republican state senators want to give Pennsylvania’s attorney general more authority to scrutinize pharmacy benefit managers, or PBMs—the opaque corporate intermediaries that decide, in large part, how pharmacies get paid, which stores stay open, and where patients can fill prescriptions.

The proposal arrives after a previous reform effort, Act 77, failed to deliver the relief many pharmacists had hoped for. That 2024 law gave the state Insurance Department new oversight tools and tried to curb some of the more controversial PBM practices, including steering patients toward affiliated pharmacies. But the law covered only a slice of the insurance market, and critics say enforcement has been weak. Meanwhile, pharmacy closures have continued, especially among independent and community stores that operate on thin margins and say they are routinely reimbursed below cost.

That is the background to the new push. The senators’ plan would let the attorney general review PBM contract renewals and terminations, intervene more directly on behalf of residents, require public hearings when disputed pharmacy terminations affect local communities, and force PBMs into Pennsylvania courts for conduct affecting Pennsylvanians. It would also bar PBMs from directly owning pharmacy licenses in the state—a provision aimed at the vertically integrated structure that critics say lets companies such as CVS act as referee, competitor, and beneficiary all at once.

The argument behind the bill is straightforward: pharmacy closures are not simply a business story. They are an access-to-care story. When a pharmacy disappears, patients travel farther, wait longer, lose trusted relationships, and sometimes struggle to get medications at all. In rural towns and urban neighborhoods alike, the pharmacy is often less a store than a piece of health infrastructure.

The deeper cause here is structural. PBMs were originally pitched as cost-saving negotiators, entities that could bargain with drugmakers and insurers to reduce prices. But over time, they became something larger and harder to see: powerful intermediaries sitting at the center of prescription-drug finance. They influence reimbursement rates, pharmacy networks, formularies, and patient routing. In theory, they create efficiency. In practice, critics argue, they have created a market in which the most important decisions about care are made through contracts that patients never read and local pharmacies cannot realistically negotiate.

That imbalance is the real subject of this story. Independent pharmacists describe a system in which they are forced into a grim choice: fill prescriptions and lose money, or stop serving patients and lose the business entirely. Even chain pharmacies, according to advocates, often have little leverage. The result is a kind of slow civic erosion. One pharmacy closure may look manageable; hundreds begin to look like policy failure.

The circumstances also reflect a broader political pattern. States are trying to regulate parts of the healthcare economy that are national in scale, legally sophisticated, and deeply entrenched. Pennsylvania’s lawmakers are reacting not only to pharmacy distress, but to the apparent inadequacy of conventional oversight. The Insurance Department, under Act 77, could regulate only so much. The attorney general’s office, by contrast, suggests a more adversarial posture: less compliance, more prosecution. This is what governments do when they conclude that a technical regulator may not be enough to confront concentrated corporate power.

And yet the politics are not entirely simple. PBMs insist they lower drug costs and support broad access to medicines. They reject blame for closures and say they depend on healthy pharmacy networks. That defense matters, because it points to the central ambiguity of the American healthcare system: nearly every actor claims to be saving money for patients, even as patients experience the system as more expensive, less accessible, and more impersonal.

The most revealing insight may be this: the fight over PBMs is really a fight over who gets to govern healthcare at the local level. Is access to medicine determined by community need, or by contract logic? Is a pharmacy a public-facing healthcare resource, or merely one dispensable node in a national reimbursement machine? Pennsylvania’s proposed bill suggests that lawmakers are beginning to understand that these are not separate questions.

What makes this moment distinctive is that the state is no longer just debating reimbursement formulas. It is edging toward a more fundamental challenge to the architecture of healthcare consolidation itself—especially the model in which one corporation can manage benefits, influence networks, and own pharmacies too. That is why this proposal matters beyond Pennsylvania. It hints at a growing bipartisan recognition that when healthcare markets become too vertically integrated, the promise of efficiency can turn into a quiet form of coercion.

In the end, the story is not only about pharmacies closing. It is about what disappears with them: convenience, trust, continuity, and the sense that healthcare still belongs, in some tangible way, to the community it serves. When those losses pile up, the problem is no longer merely economic. It becomes democratic.